

4-1-2017

# Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases.

A Hinks

J Bowes

J Cobb

H C. Ainsworth

M C. Marion

*See next page for additional authors*

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/papers>

 Part of the [Medical Genetics Commons](#), [Pediatrics Commons](#), and the [Rheumatology Commons](#)

---

## Recommended Citation

Hinks, A; Bowes, J; Cobb, J; Ainsworth, H C.; Marion, M C.; Comeau, M E.; Sudman, M; Han, B; Juvenile Arthritis Consortium for Immunochip; Becker, Mara L.; Bohnsack, J F.; de Bakker, P I W.; Haas, J P.; Hazen, M; Lovell, D J.; Nigrovic, P A.; Nordal, E; Punaro, M; Rosenberg, A M.; Rygg, M; Smith, S L.; Wise, C A.; Videm, V; Wedderburn, L R.; Yarwood, A; Yeung, R S M; Prahalad, S; Langefeld, C D.; Raychaudhuri, S; Thompson, S D.; and Thomson, W, "Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases." (2017). *Manuscripts, Articles, Book Chapters and Other Papers*. 452.

<https://scholarlyexchange.childrensmercy.org/papers/452>

---

**Creator(s)**

A Hinks, J Bowes, J Cobb, H C. Ainsworth, M C. Marion, M E. Comeau, M Sudman, B Han, Juvenile Arthritis Consortium for Immunochip, Mara L. Becker, J F. Bohnsack, P I W de Bakker, J P. Haas, M Hazen, D J. Lovell, P A. Nigrovic, E Nordal, M Punnaro, A M. Rosenberg, M Rygg, S L. Smith, C A. Wise, V Videm, L R. Wedderburn, A Yarwood, R S M Yeung, S Prahalad, C D. Langefeld, S Raychaudhuri, S D. Thompson, and W Thomson



OPEN ACCESS

## EXTENDED REPORT

# Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases

A Hinks,<sup>1</sup> J Bowes,<sup>1</sup> J Cobb,<sup>1,2</sup> H C Ainsworth,<sup>3</sup> M C Marion,<sup>3</sup> M E Comeau,<sup>3</sup> M Sudman,<sup>4</sup> B Han,<sup>5,6</sup> Juvenile Arthritis Consortium for Immunochip, M L Becker,<sup>7</sup> J F Bohnsack,<sup>8</sup> P I W de Bakker,<sup>9</sup> J P Haas,<sup>10</sup> M Hazen,<sup>11</sup> D J Lovell,<sup>12</sup> P A Nigrovic,<sup>11,13</sup> E Nordal,<sup>14</sup> M Punaro,<sup>15,16</sup> A M Rosenberg,<sup>17</sup> M Rygg,<sup>18</sup> S L Smith,<sup>1</sup> C A Wise,<sup>19,20</sup> V Videm,<sup>18</sup> L R Wedderburn,<sup>21,22</sup> A Yarwood,<sup>1</sup> R S M Yeung,<sup>23</sup> S Prahalad,<sup>24</sup> C D Langefeld,<sup>3</sup> S Raychaudhuri,<sup>1,5,25,26</sup> S D Thompson,<sup>4</sup> W Thomson<sup>1,2</sup>

**Handling editor** Tore K Kvien

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2016-210025>).

For numbered affiliations see end of article.

**Correspondence to**

Dr Anne Hinks, Arthritis Research UK Centre for Genetics and Genomics, Manchester Academic Health Science Centre, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK; Anne.Hinks@manchester.ac.uk

AH and JB contributed equally.

SDT and WT contributed equally as senior authors.

Received 7 June 2016  
Revised 12 September 2016  
Accepted 5 November 2016  
Published Online First  
20 December 2016

**ABSTRACT**

**Objectives** Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases, comprising seven categories. Genetic data could potentially be used to help redefine JIA categories and improve the current classification system. The human leucocyte antigen (HLA) region is strongly associated with JIA. Fine-mapping of the region was performed to look for similarities and differences in HLA associations between the JIA categories and define correspondences with adult inflammatory arthritides.

**Methods** Dense genotype data from the HLA region, from the Immunochip array for 5043 JIA cases and 14 390 controls, were used to impute single-nucleotide polymorphisms, HLA classical alleles and amino acids. Bivariate analysis was performed to investigate genetic correlation between the JIA categories. Conditional analysis was used to identify additional effects within the region. Comparison of the findings with those in adult inflammatory arthritic diseases was performed.

**Results** We identified category-specific associations and have demonstrated for the first time that rheumatoid factor (RF)-negative polyarticular JIA and oligoarticular JIA are genetically similar in their HLA associations. We also observe that each JIA category potentially has an adult counterpart. The RF-positive polyarthritis association at HLA-DRB1 amino acid at position 13 mirrors the association in adult seropositive rheumatoid arthritis (RA). Interestingly, the combined oligoarthritis and RF-negative polyarthritis dataset shares the same association with adult seronegative RA.

**Conclusions** The findings suggest the value of using genetic data in helping to classify the categories of this heterogeneous disease. Mapping JIA categories to adult counterparts could enable shared knowledge of disease pathogenesis and aetiology and facilitate transition from paediatric to adult services.

**INTRODUCTION**

Juvenile idiopathic arthritis (JIA), the most common arthritic disease of childhood, is a heterogeneous

group of diseases. The current International League of Associations for Rheumatology (ILAR) classification system defines seven categories based on clinical features, including an undifferentiated category for cases that do not fall into one of the defined categories.<sup>1</sup> Genetic data could be used to help define JIA categories and improve the current classification system. Prior studies of the best established genetic risk factor for JIA, the major histocompatibility region (MHC) on chromosome 6, have been in modest sample sizes.<sup>2,3</sup> The development of methods for imputation of classical human leucocyte antigen (HLA) alleles and amino acids<sup>4</sup> from genotyping array data enables a comprehensive and cost-effective approach for generating HLA typing on much larger JIA cohorts. We sought to use this powerful approach to dissect and refine the HLA associations of the heterogeneous JIA categories.

While there are considerable clinical similarities between some JIA categories and adult inflammatory arthritides, there is also substantial heterogeneity. Hence, we sought to compare the associations across the MHC region observed in JIA cohorts with those observed in adult inflammatory arthritides, such as rheumatoid arthritis (RA).<sup>5,6</sup> Furthermore, some categories of JIA have obvious adult counterparts (eg, enthesitis-related arthritis (ERA) and adult ankylosing spondylitis (AS), or juvenile psoriatic arthritis (jPsA) with psoriatic arthritis), the most common categories of JIA, oligoarthritis and rheumatoid factor (RF)-negative polyarthritis, do not appear to map to any adult form of disease. Mapping each of the JIA categories to RA and other adult inflammatory arthritic diseases could have many benefits including enhanced understanding of the genetic basis and etiopathogenesis of inflammatory arthritis in general, allow extrapolation of results from clinical trials in adult inflammatory arthritis to paediatric counterparts to improve the therapy of JIA, and facilitate smooth transition of paediatric patients to adult care providers with consistent clinical designations.



CrossMark

**To cite:** Hinks A, Bowes J, Cobb J, et al. *Ann Rheum Dis* 2017;**76**:765–772.

The goals of this study were threefold, to use comprehensive MHC fine-mapping genetic data to refine HLA associations across each JIA category, to assess correspondences between the JIA categories and finally compare associations with adult inflammatory arthritic diseases.

## METHODS

### Subjects

All cohorts comprised individuals from populations of European descent from the USA, UK, Canada, Norway and Germany. Descriptions of the datasets can be found in the online supplementary information. The total dataset prequality control comprised all JIA categories and included 5737 patients with JIA and 16 403 controls genotyped for 191 494 markers.

### Genotyping and quality controls

Samples were genotyped using ImmunoChip, a custom-made Illumina Infinium array, described previously.<sup>7</sup> The ImmunoChip includes dense coverage of the HLA region and 186 additional non-HLA loci. Genotyping was performed according to Illumina's protocols at labs in Hinxton, UK, Manchester, UK, Cincinnati, USA, Utah, USA, Charlottesville, USA, New York, USA, Brisbane, Australia and Toronto, Canada. The Illumina GenomeStudio GenTrain V2.0 algorithm was used to recluster all 22 140 samples together.

Single-nucleotide polymorphisms (SNPs) were initially excluded if they had a call rate <98% and a cluster separation score of <0.4. A SNP was subsequently removed from the primary analysis, if it exhibited significant differential missingness between cases and controls ( $p < 0.05$ ), had significant departure from Hardy-Weinberg equilibrium ( $p < 0.000001$  in cases or  $p < 0.01$  in controls), or had a minor allele frequency (MAF) <0.01. Based on the SNPs that passed the above quality control thresholds, samples were then excluded for call rate <98%, or if there were inconsistencies between recorded and genotype-inferred gender or excess heterozygosity on the autosomes. Duplicates and first-degree or second-degree relatives were removed based on identity-by-descent statistics computed using the programme KING.<sup>8</sup> Admixture estimates were computed on the remaining samples while including the HapMap phase III individuals (CEU, YRI and CHB) as reference populations using the software ADMIXTURE.<sup>9</sup> The admixture estimates were then used to identify and remove genetic outliers. Three of these admixture estimates were included as covariates in the logistic regression (association) analysis to account for within-sample variation.

### HLA imputation

The markers spanning 29–34 Mb (hg build19) on chromosome 6 which encompasses the HLA region were extracted from the post-QC ImmunoChip dataset. Cases and controls were imputed together using SNP2HLA (V1.0) (<http://www.broadinstitute.org/mpg/snp2hla/>).<sup>4</sup> This is a robust approach which enables imputation of classical HLA alleles as well as specific amino acid positions within HLA alleles, which may play an important functional role. The method uses a large reference dataset collected by the type 1 diabetes genetics consortium<sup>10</sup> ( $n = 5225$ ). This dataset has gold-standard HLA typing and high SNP density, thus using linkage disequilibrium patterns around SNPs and classical HLA alleles enables the inference of classical HLA alleles, amino acids and SNPs across the region based on the SNP data generated from ImmunoChip, an approach successfully used by a number of researchers.<sup>5 6 11 12</sup> Post-imputation QC included removing variants with a MAF <0.01 and variants

with an  $r^2 < 0.8$ . The dosage output, which accounts for imputation uncertainty, was used for the association analyses.

To assess the quality of the imputation, a proportion of the UK and the US JIA cases have two-digit and four-digit *HLA-DRB1* typing available ( $n = 1562$ ) performed using a semi-automated, reverse dot-blot method,<sup>2 3</sup> which was used to calculate the proportion of accurately imputed two-digit and four-digit *HLA-DRB1* alleles. In addition, the *DRB1* two-digit and four-digit allele frequencies were compared between genotyped and imputed HLA allele calls.

### Association analysis of HLA alleles and amino acid polymorphisms

To compare the differences and similarities of HLA associations across the different JIA categories, genetic correlation of the MHC region between the categories was calculated using bivariate analysis<sup>13</sup> implemented using GCTA.<sup>14</sup> This analysis first calculates the genetic variance (heritability) of each category and then calculates the genetic correlation between the categories across the HLA region. High correlation suggests similarities or pleiotropy between the two categories compared. This analysis requires independent controls for the two categories being compared and therefore the controls were randomly assigned to the two categories, splitting equally, taking into account the proportions of controls from each population.

HLA variants were binary coded (presence or absence) and included SNPs and two-digit and four-digit HLA alleles. Association analysis was performed using logistic regression in R, using dosage data (genotype probabilities), which takes into account imputation uncertainty. For the analysis of each JIA category, the total control dataset was used for each comparison. HLA amino acid polymorphisms have multiple residues at each position and were analysed using the omnibus test. This is a log-likelihood ratio test comparing the likelihood of the null model against the likelihood of the fitted model, which gave a  $p$  value assessing the improvement in fit of the model, the deviance is calculated ( $-2 \times$  the log likelihood ratio), which follows a  $\chi^2$  distribution with  $m-1$  degrees of freedom (where  $m$  is the number of HLA variant alleles).<sup>5</sup> Three of the admixture estimates were included as covariates to account for potential population stratification.

To look for independent effects across the HLA region, conditional analysis was performed. Logistic regression, as described above, was performed to identify the most associated marker. Then this marker was used as a covariate in the model and logistic regression repeated. This analysis was continued sequentially in a forward stepwise approach until no variant satisfied the genome-wide significance threshold (conditioned  $p < 5 \times 10^{-8}$ ). When the covariate was an amino acid, all multi-allelic variants of the amino acid were included as covariates, excluding the most frequent variant. To look for additional effects outside *HLA-DRB1*, we included all two-digit and four-digit *HLA-DRB1* alleles within the model and looked for any residual effects.

To confirm the results of the conditional analysis and to check that there were no other combinations of variants that better fitted the models derived from the forward stepwise approach, described above, we exhaustively tested all possible combinations of 2, 3 and 4 amino acid positions, including the three admixture estimates as covariates. For each combination we calculated deviation from the null hypothesis, which included only the admixture covariates. To assess the improvement in the model fit we also calculated the improvement in the Akaike information criterion ( $\Delta AIC$ ), and also the improvement in the Bayesian information criterion ( $\Delta BIC$ ).

We used a disease prevalence of 0.001 to estimate the variance explained ( $h^2$ ) by the HLA region and some of the independent effects and compared with the estimate calculated for all Immunochip, implemented using GCTA.<sup>14</sup>

## RESULTS

### HLA imputation

Post-QC data was available for 6920 SNPs, 335 amino acids and 171 HLA alleles in 5043 JIA cases and 14 390 healthy controls (see online supplementary table S1). A detailed breakdown of the JIA cases by ILAR category is shown in table 1, and by population and gender in online supplementary table S2.

For a proportion of the UK and US JIA cases ( $n=1562$ ), two-digit and four-digit HLA-DRB1 classical typing was available. The accuracy of the imputed data was calculated as 97.9% for two-digit and 89.3% for four-digit alleles, which is similar to those calculated in previous studies in RA.<sup>5</sup> A detailed analysis strategy is shown in online supplementary figure S1.

### Bivariate analysis to look for genetic correlation between the JIA categories

We performed bivariate analysis to calculate the estimated HLA region genetic correlation between each pair of JIA categories (figure 1). The heritability for each category estimated from the bivariate analysis was similar to that estimated from univariate analyses performed in the total dataset (see online supplementary tables S3 and S4). The estimates of correlation between each pair of JIA categories showed a surprisingly strong correlation between the most common categories of JIA: RF-negative polyarthritis, persistent and extended oligoarthritis ( $r_G > 0.88$ ). In contrast, the correlations between these three categories and the other categories of JIA were lower (figure 1).

### Association analysis of HLA markers

After conducting primary association analysis of all 7426 variants, in each of the seven JIA categories (table 2), we observed that for oligoarthritis and both RF-positive and RF-negative polyarthritis the strongest association was with *HLA-DRB1* amino acid position 13. However, for oligoarthritis and RF-negative polyarthritis, the most common categories of JIA, glycine13 confers the strongest risk; serine13 also confers a risk effect but histidine13 is protective. By contrast, in RF-positive polyarthritis, it is histidine13 that confers the strongest risk and serine13 confers a strong protective effect (see figure 2, online

supplementary table S5 and supplementary figure S2). When the effect estimates for the histidine13 residue in the associated JIA categories were compared using multinomial logistic regression, strong protective effects were observed in persistent and extended oligoarthritis, with no significant difference in the effect estimates ( $p=0.63$ ). There was a slightly weaker, protective effect for RF-negative polyarthritis compared with that for persistent and extended oligoarthritis ( $p < 0.05$ ). Importantly, there was a significantly different risk effect in RF-positive polyarthritis compared with RF-negative polyarthritis, persistent and extended oligoarthritis. The remaining JIA categories had distinct HLA associations from these common categories. The most significant association in systemic JIA (sJIA) was for *HLA-DRB1\*11* and for the ERA category was *HLA-B\*27*. For jPsA, no associations reached genome-wide level of significance ( $p < 5 \times 10^{-8}$ ).


### Investigation of multiple effects within the region

Observing that oligoarthritis and RF-negative polyarthritis showed similar HLA associations and evidence for pleiotropy from the bivariate analysis in GCTA,<sup>13 14</sup> these categories were combined to increase power for further analyses (total sample size=3934). To look for independent genetic effects across the HLA region, we conditioned on the most associated marker, *HLA-DRB1* amino acid 13 and detected a second independent effect within *HLA-DRB1* at amino acid position 67 (omnibus  $p=7.01 \times 10^{-83}$ ). Further conditioning revealed separate effects at amino acid positions 181 (omnibus  $p=3.33 \times 10^{-22}$ ) and 71

**Table 1** Breakdown of the total JIA cohort by ILAR category

ILAR category	Number
All JIA	5043
Systemic JIA	373
Oligoarthritis	
Persistent	1751
Extended	658
RF-negative polyarthritis	1525
RF-positive polyarthritis	337
Enthesitis-related arthritis	183
Juvenile psoriatic arthritis	112
Undifferentiated	104
Combined oligoarthritis and RF-negative polyarthritis dataset	3934

ILAR, International League of Associations for Rheumatology; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor.



**Figure 1** Heatmap showing genetic correlation for human leucocyte antigen (HLA) between the juvenile idiopathic arthritis (JIA) categories. Each square shows the level of correlation between each JIA category. With a scale of red colour representing higher correlation through orange to yellow for low correlation. The numbers within the squares represent the correlation values ranging from 0 to 1 for high correlation. Note that this plot is symmetrical. POLigo, persistent oligoarthritis; EOligo, extended oligoarthritis; RF, rheumatoid factor; RFnegpoly, RF-negative polyarthritis; RFpospoly, RF-positive polyarthritis; sJIA, systemic JIA; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis.



**Table 2** Primary association of the HLA region in JIA ILAR categories

Category	HLA variant primary association	Position	p Value	Amino acid residue	OR	95% CI
Systemic JIA	<i>HLA-DRB1*11</i>	32660042	$3.41 \times 10^{-11}$		2.09	1.67 to 2.59
Persistent oligoarthritis	<i>HLA-DRB1</i> AA pos 13	32660109	$9 \times 10^{-256}$	Glycine	2.72	2.41 to 3.08
Extended oligoarthritis	<i>HLA-DRB1</i> AA pos 13	32660109	$1.05 \times 10^{-104}$	Glycine	2.87	2.4 to 3.42
RF-negative polyarthritis	<i>HLA-DRB1</i> AA pos 13	32660109	$4.29 \times 10^{-99}$	Glycine	2.02	1.76 to 2.32
RF-positive polyarthritis	<i>HLA-DRB1</i> AA pos 13	32660109	$3.65 \times 10^{-31}$	Histidine	2.44	2.0 to 2.97
ERA	<i>HLA-B*27</i>	31431272	$8.81 \times 10^{-98}$		1.71	1.32 to 2.24

ERA, enthesitis-related arthritis; HLA, human leucocyte antigen; ILAR, International League of Associations for Rheumatology; JIA, Juvenile idiopathic arthritis; RF, rheumatoid factor.

(omnibus  $p=1.16 \times 10^{-8}$ ) (see online supplementary table S6 and supplementary figure S3). Conditioning on all two-digit and four-digit *HLA-DRB1* alleles found independent effects at *HLA-DPB1\*02:01*, *HLA-A* amino acid 95 and *HLA-B* amino acid 152 (see online supplementary table S6 and figure 3). All possible combinations of 2, 3 and 4 amino acids in *HLA-DRB1* were exhaustively tested. *HLA-DRB1* amino acids 13 and 67 were the most strongly associated of all possible 2 amino acid combinations. However, for both the 3- amino acid and 4-amino acid combinations, there were two other combinations that had a better model, according to deviance from the null hypothesis, compared with the combination of *HLA-DRB1* amino acids at positions 13, 67 and 181 or for *HLA-DRB1* at positions 13, 67, 181 and 71, the 3- and 4-amino acid models that might have been expected to be the most significant considering the results of the conditional analysis. Therefore, while there appears to be multiple independent effects within the *HLA-DRB1* gene, we can only be confident in the *HLA-DRB1* amino acids at positions 13 and 67.

### Variance explained by the HLA region

We calculated the proportion of variance explained by the independent HLA variants in the combined oligoarthritis and RF-negative polyarthritis dataset (see table 3 and online supplementary table S4) and found that the total HLA region


explained 8% of the total phenotypic variance, with the *HLA-DRB1* region, driven by the amino acid at position 13, contributing 50% of variance explained by the HLA region.

### Comparison with adult inflammatory arthritic diseases


We compared our HLA association findings across JIA categories with those of adult inflammatory arthritic diseases (see online supplementary table S7). In seropositive RA, Raychaudhuri *et al* showed multiple independent associations within the *HLA-DRB1* gene at three amino acid positions (11, 71 and 74) and also independent associations at amino acid position 9 in *HLA-B* and amino acid position 9 in *HLA-DPB1*.<sup>5</sup> The DRB1 amino acid at position 11 is in strong linkage disequilibrium with the amino acid at position 13, which makes it difficult to assign causality to one or the other. In this study, oligoarthritis and polyarthritis each showed association with *HLA-DRB1* amino acid at position 13. If the ORs of the residues at *HLA-DRB1* amino acid position 13 for paediatric and adult arthritic diseases are compared, the combined oligoarthritis and RF-negative polyarthritis dataset shows similar ORs to that seen in seronegative RA<sup>6</sup> (see online supplementary figure S4), suggesting that these JIA categories could potentially have an adult counterpart. Likewise, in RF-positive polyarthritis, the histidine residue at position 13 at *HLA-DRB1* confers the greatest risk for disease and, unsurprisingly, this mirrors the association in seropositive RA<sup>5</sup> (see online supplementary figure S4). For the ERA category, as expected the most significant association was for *HLA-B\*27*, the same HLA allele found in AS.

### DISCUSSION

This is the largest investigation of association of the HLA region with JIA and its categories to date, exploiting novel imputation strategies we have observed differences and similarities between HLA associations for the different categories. The most common and also the most clinically homogeneous categories of JIA, oligoarthritis and RF-negative polyarthritis, showed strong genetic correlation across the HLA region supporting our previous approaches of combining these categories for genetic studies.<sup>15</sup> Combined analysis of these categories show they share association across the HLA region with strong association for *HLA-DRB1* amino acid position 13. The results for these combined categories are consistent with previous findings investigating association of classical HLA alleles in JIA. For example, there is previous evidence for association of *HLA-DRB1\*08* and the HLA alleles that lie on this haplotype, with oligoarthritis and RF-negative polyarthritis.<sup>2,3</sup> At *HLA-DRB1* amino acid position 13, the glycine residue lies on the *HLA-DRB1\*08* haplotype. The association with the amino acids is much stronger than that for the classical HLA allele (see online supplementary figure S3A). These combined categories also show multiple independent effects across the region, at *HLA-DRB1* amino acid



**Figure 2** Different effect sizes (ORs and 95% CIs) for amino acid residues at human leucocyte antigen (*HLA*)-*DRB1* position 13 between the combined dataset of oligoarthritis and rheumatoid factor (RF)-negative polyarthritis compared with those for RF-positive polyarthritis.



**Figure 3** Analysis in the combined dataset of persistent and extended oligoarthritis and rheumatoid factor (RF)-negative polyarthritis, evidence for multiple independent effects across the major histocompatibility region (MHC). (A) Association results for all human leucocyte antigen (HLA) markers, *HLA-DRB1* amino acid position 13 showed the strongest association ( $p < 10^{-377}$ ). (B) Conditioning on all *HLA-DRB1* two-digit and four-digit alleles, *HLA-DPB1\*02:01* was associated ( $p < 10^{-57}$ ). (C) Conditioning on all *HLA-DRB1* two-digit and four-digit alleles and *HLA-DPB1\*02:01*, *HLA-A* amino acid position 95 was associated ( $p < 10^{-37}$ ). (D) Conditioning on all *HLA-DRB1* two-digit and four-digit alleles, *HLA-DPB1\*02:01* and *HLA-A* amino acid position 95, *HLA-B* amino acid position 152 was associated ( $p < 10^{-10}$ ).

**Table 3** Heritability estimates for HLA and various alleles and All Immunochip in the combined oligoarthritis and RF-negative polyarthritis dataset (n=3934)

Cohort	$h_{SNP}^2$ (SE)
All Immunochip	0.17 (0.006)
Total HLA region	0.08 (0.007)
All Immunochip without HLA	0.09 (0.006)
<i>HLA-DRB1</i> 2D/4D alleles	0.04 (0.008)
<i>HLA-DPB1</i> 2D/4D alleles	0.02 (0.005)
<i>HLA-A</i> 2D/4D alleles	0.006 (0.002)
<i>HLA-DRB1</i> amino acid position 13	0.04 (0.02)
<i>HLA-DRB1</i> amino acid positions 13 and 67	0.04 (0.02)

$h_{SNP}^2$ , heritability; HLA, human leucocyte antigen; RF, rheumatoid factor.

position 67, additional association at *HLA-DPB1\*02:01*, an effect at *HLA-A* and at *HLA-B*. There is previous evidence for association of *HLA-DPB1\*0201* and *HLA-A\*02* (we found stronger association considering amino acids, specifically a valine residue at *HLA-A* amino acid position 95 in *HLA-A\*02*). Previous studies have failed to demonstrate an association with *HLA-B*, which are apparent only with the additional samples available for this study.

A striking finding has been the shared association of *HLA-DRB1* amino acid position 13 for both paediatric and adult diseases. It is known that amino acid position 13 is involved in shaping the peptide-binding pocket 4 of *HLA-DRB1*.<sup>16</sup> We find that the association in the combined oligoarthritis and RF-negative polyarthritis dataset mirrors the findings seen in seronegative RA and similarly, in RF-positive polyarthritis, the findings correspond to the association in seropositive RA. Interestingly, the magnitudes of associations are stronger in the paediatric diseases compared with adult, suggesting the paediatric disease is more genetically driven.

We then further compared the associations seen in each of the other JIA categories with those of their proposed adult counterparts. Based on clinical features, it is likely that sJIA would map to adult Still's disease, but there is currently no HLA genetic data to support or refute this. The most significant association in sJIA was for *HLA-DRB1\*11*, consistent with recent findings from a large genome-wide association study for sJIA, which used an overlapping set of samples.<sup>17</sup> Previous studies of a HLA association with sJIA had yielded conflicting results, but there is now clear evidence for association of the HLA region with this category of JIA. Data from the current study also show that the association is distinct to that seen in the other categories. This supports emerging evidence that sJIA is a distinct disease, with less of an autoimmune phenotype and displaying auto-inflammatory features<sup>18</sup> and builds on previous genetic evidence, which reported no association with another well-established JIA susceptibility gene, *PTPN22*, in sJIA.<sup>19</sup> Unsurprisingly, the strongest association seen in ERA, *HLA-B\*27*, is the same as adult AS.<sup>20</sup> Although no associations reaching genome-wide level of significance ( $p < 5 \times 10^{-8}$ ) were seen in jPsA, the most significant HLA alleles were *HLA-DQA1\*0401* ( $p=0.0001$ ), *HLA-DRB1\*08* ( $p=0.0003$ ) and *HLA-DQB1\*0402* ( $p=0.0008$ ), which all lie on the same haplotype. The established HLA association in adult-onset PsA is *HLA-C\*0602*,<sup>21</sup> which is also the primary HLA association in psoriasis,<sup>22</sup> was also modestly associated in this study ( $p=0.008$ ). There was also evidence in jPsA for association with *HLA-B\*27* ( $p=0.003$ ), the HLA allele that is the most

significant in ERA. The mixed HLA associations in jPsA may suggest some misclassification such that the jPsA samples may contain some individuals from oligoarthritis, RF-negative polyarthritis or ERA categories. This is perhaps not surprising given that jPsA is difficult to classify, and that some of the jPsA classification criteria have been disputed.<sup>23</sup>

The results of this study have important implications for understanding disease pathogenesis, aetiology and potential future therapeutic strategies for JIA categories. Despite the development of a classification system, heterogeneity still exists within the ILAR categories. This heterogeneity of JIA remains a key challenge to paediatric rheumatologists; however, these results may inform the debate on classification and help define a more biological-driven and molecular-driven classification system. We show clear differences among many of the categories in terms of their HLA associations, but here we have also shown that the most common categories of JIA, oligoarthritis and RF-negative polyarthritis, are genetically similar and also notably similar to adult-onset seronegative RA. It is only relatively recently that the heterogeneous nature of adult RA has been recognised, with seronegative RA less common than seropositive RA.<sup>24 25</sup> There are no specific therapeutic strategies for seronegative RA at this time, but given the rarity of this subphenotype of RA and the JIA categories individually, this study suggests that further comparisons of genetic studies for these diseases could help identify novel pathways and targets for therapy for both adult-onset and childhood-onset forms of inflammatory arthritis.

#### Author affiliations

<sup>1</sup>Arthritis Research UK Centre for Genetics and Genomics, Manchester Academic Health Science Centre, University Of Manchester, Manchester, UK

<sup>2</sup>NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

<sup>3</sup>Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

<sup>4</sup>Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

<sup>5</sup>Divisions of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

<sup>6</sup>Department of Convergence Medicine, University of Ulsan College of Medicine & Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea

<sup>7</sup>Division of Rheumatology and Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA

<sup>8</sup>Division of Allergy, Immunology and Paediatric Rheumatology, University of Utah, Salt Lake City, Utah, USA

<sup>9</sup>Department of Medical Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

<sup>10</sup>German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany

<sup>11</sup>Division of Immunology, Department of Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA

<sup>12</sup>Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

<sup>13</sup>Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA

<sup>14</sup>Department of Paediatrics, University Hospital of North Norway, and UIT The Arctic University of Norway, Tromsø, Norway

<sup>15</sup>Arthritis Clinic Texas Scottish Rite Hospital for Children, Dallas, Texas, USA

<sup>16</sup>Department of Paediatrics, UT Southwestern Medical Center, Dallas, Texas, USA

<sup>17</sup>Division of Rheumatology, Department of Paediatrics, University of Saskatchewan, Saskatoon, Canada

<sup>18</sup>Department of Laboratory Medicine, Children's and Women's Health, NTNU - Norwegian University of Science and Technology, and St. Olavs University Hospital, Trondheim, Norway

<sup>19</sup>Sarah M. and Charles E. Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas, Texas, USA

<sup>20</sup>Department of Orthopaedic Surgery, Paediatrics, and McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, Texas, USA

<sup>21</sup>Arthritis Research UK Centre for Adolescent Rheumatology, UCL GOS Institute of Child Health, University College London, London, UK

<sup>22</sup>NIHR-Great Ormond Street Hospital Biomedical Research Centre, London, UK



<sup>23</sup>The Hospital for Sick Children and University of Toronto, Toronto, Canada

<sup>24</sup>Department of Paediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, USA

<sup>25</sup>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, USA

<sup>26</sup>Department of Medicine, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden

**Twitter** Follow Paul de Bakker @Pwdb, Soumya Raychaudhuri @soumya\_boston and University of Manchester, Centre for Musculoskeletal disease @UoMMskResearch

**Acknowledgements** We thank Paul Gilbert for preparing the UK JIA case samples for genotyping and Mary Ryan for preparing the US JIA and the Cincinnati local control samples.

Genotyping of the US JIA, German JIA and respective control collections was supported by RC1-AR-058587 and U01-AI-06715051. In addition, patient recruitment and DNA preparation in the USA was largely funded by N01-AR-42272, P01-AR-048929 and P30-AR-473639, with contributions from the Arthritis Foundation, The Val A. Browning Charitable Foundation in Salt Lake City and the Marcus Foundation in Atlanta, GA as well as National Institutes of Health (NIH) grants K23-AR-50177 and R01-AR-060893. The Federal Ministry of Education and Research, Germany (BMBF grants 01GM0907 and 01 ZZ 0403 supported patient recruitment and sample preparation in Germany. We acknowledge support from the Wake Forest School of Medicine Center for Public Health Genomics and from the NIH for computing resources and data analysis (R01-AR-057106).

Genotyping of the UK JIA cases samples was supported by the Arthritis Research UK grant reference number 20385. This report includes independent research funded by the National Institute for Health Research Biomedical Research Unit. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. The Arthritis Research UK centre for Genetics and Genomics laboratory is supported by the Manchester Academic Health Sciences Centre (MAHSC). The CAPS study was funded by Arthritis Research UK grant reference 20542. The CHARMS study was funded by Sparks UK, reference 081CH09, and the Medical Research Council, reference MR/M004600/1, and supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London and Clinical Research Network (CRN). The authors would like to acknowledge the assistance given by IT Services and the use of the Computational Shared Facility at The University of Manchester.

Patient recruitment and DNA preparation in Canada was supported by funding from the Canadian Institutes of Health Research (FRN-82517), The Canadian Arthritis Society and the Canadian Arthritis Network.

We acknowledge Nils Thomas Songstad and Nina Moe for patient recruitment in the Norwegian subcohort of the Nordic JIA study, Kristin Rian for technical support and Helse Nord Research Grants for funding. The HUNT study is a collaboration between the HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council, Central Norway Health Authority and the Norwegian Institute of Public Health. Johanna Hadler, Katie Cremin, Karena Pryce and Jessica Harris are acknowledged for excellent technical assistance.

Sample recruitment was supported in part by grant numbers N01AR62277, GM103510, AI082714 and AR053483 from NIAMS/NIGMS/NIAD/NIH and from grant number 1296353 from the Texas Scottish Rite Hospital for Children. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of these institutes or NIH. PAN was supported by the Fundación Bechara. SR is supported by grants from the NIH (1R01AR063759 (SR), 5U01GM092691-05 (SR), 1UH2AR067677-01, U19 AI11224-01) and the Doris Duke Charitable Foundation Grant #2013097.

We would like to thank the WTSI Genotyping Facility and in particular Emma Gray, Sue Bumpstead, Doug Simpkin and Hannah Blackburn for typing some of the UK samples. We acknowledge use of DNA from the UK Blood Services collection of common controls (UKBS-CC collection), which is funded by the Wellcome Trust grant 076113/C/04/Z and by the US NIHR programme grant to the National Health Service Blood and Transplant (RP-PG-0310-1002). We acknowledge the use of DNA from the British 1958 Birth Cohort Collection, which is funded by the UK Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/01. Genotyping of control samples was supported, in part, by grants from the Juvenile Diabetes Research Foundation International and the NIH (U01 DK062418).

We thank Peter K. Gregersen at the Feinstein Institute for providing the US control genotyping from the Genotype and Phenotype registry (<http://www.gapregistry.org>) supported by the NIH grant RC2AR059092. We thank the NIDDK IBD Genetics Consortium for providing North American control genotyping supported by the NIH grants DK062431, DK062422, DK062420, DK062432, DK062423, DK062413 and DK062429.

We gratefully acknowledge contributions from physicians at CCHMC and collaborating clinics. We also acknowledge the assistance of Bronte Clifford and Lori Ponder for patient recruitment and coordination of clinical information at Cincinnati

Children's Hospital Medical Center, the University of Utah and at Emory University, respectively. The Cincinnati normal control DNA collection was supported and made available by Cincinnati Children's Hospital Medical Center.

**Contributors** WT, SDT, SR, CDL, SP, JB and AH led the study. AH, JB, SR, CDL, SP, SDT and WT wrote the paper. AH, JB, JC, HCA, MCM, MEC, MS, BH, CDL and SR performed the data and statistical analysis. MLB, JFB, PIWdB, JPH, MH, DJL, PAN, EN, MP, AMR, MR, SLS, CAW, VV, LRW, AY, RSMY contributed to the patient ascertainment, sample collection and/or genotyping. All authors reviewed the final manuscript.

**Collaborators** Juvenile Arthritis Consortium for Immunochip: full list of affiliations for consortia will appear in the online supplementary information.

**Funding** Wellcome Trust (068545/Z/01, 076113/C/04/Z); for statistical support at Wake-Forest, National Institutes of Health (NIH) grant (R01-AR-057106); National Institute for Health Research programme grant, (RP-PG-0310-1002); Doris Duke Charitable Foundation Grant (2013097); NIH (10.13039/100000002, U01 DK062418, RC2AR059092, DK062431, DK062422, DK0); for Utah samples, NIH grants (K23-AR-50177 and R01-AR-060893); UK samples, Sparks UK (081CH09); for the UK samples and support, Arthritis Research UK (20385 and 20542); Medical Research Council (G0000934, MR/M004600/1); Canadian Institutes of Health Research (FRN-82517); the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology; NIH Federal Ministry of Education and Research, Germany (01GM0907 and 01 ZZ 0403); SR is supported by grants from the NIH (1R01AR063759); genotyping of the US JIA, German JIA and respective control collections was supported by NIAMS/NIGMS/NIAD/NIH (RC1-AR-058587, U01-AI-06715051, N01-AR-42272, P01); Juvenile Diabetes Research Foundation International; the US sample recruitment was supported in part by NIAMS/NIGMS/NIAD/NIH and from Texas Scottish Rite Hospital for Children (N01AR62277, GM103510, AI082714, AR053483, 1296353. Patient recruitment and DNA preparation in Canada was supported by funding from the Canadian Institutes of Health Research (FRN-82517), the Canadian Arthritis Society and the Canadian Arthritis Network.

**Competing interests** LRW reports Honorarium for speaker at Symposium from Pfizer Inc. SP has been on advisory boards for Novartis, medac and UCB pharma. None of these had any bearing on the work reported in this publication.

**Ethics approval** North-West Multi-Centre Research Ethics Committee (MREC 99/8/84), the University of Manchester Committee on the Ethics of Research on Human Beings and National Research Ethics Service (NRES 02/8/104).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Additional data are included in the online supplementary data.

**Open Access** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>

## REFERENCES

- Petty RE, Southwood TR, Manners P, *et al*. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol* 2004;31:390–2.
- Thomson W, Barrett JH, Donn R, *et al*. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. *Rheumatology (Oxford)* 2002;41:1183–9.
- Hollenbach JA, Thompson SD, Bugawan TL, *et al*. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. *Arthritis Rheum* 2010;62:1781–91.
- Jia X, Han B, Onengut-Gumuscu S, *et al*. Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS ONE* 2013;8:e64683.
- Raychaudhuri S, Sandor C, Stahl EA, *et al*. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. *Nat Genet* 2012;44:291–6.
- Han B, Diogo D, Eyre S, *et al*. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. *Am J Hum Genet* 2014;94:522–32.
- Cortes A, Brown MA. Promise and pitfalls of the Immunochip. *Arthritis Res Ther* 2011;13:101.
- Manichaikul A, Mychaleckyj JC, Rich SS, *et al*. Robust relationship inference in genome-wide association studies. *Bioinformatics* 2010;26:2867–73.
- Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. *Genome Res* 2009;19:1655–64.
- Brown WM, Pierce J, Hillner JE, *et al*. Overview of the MHC fine mapping data. *Diabetes Obes Metab* 2009;11(Suppl 1):2–7.

- 11 Hu X, Deusch AJ, Lenz TL, *et al.* Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk. *Nat Genet* 2015;47:898–905.
- 12 Gutierrez-Achury J, Zernakova A, Pulit SL, *et al.* Fine mapping in the MHC region accounts for 18% additional genetic risk for celiac disease. *Nat Genet* 2015;47:577–8.
- 13 Lee SH, Yang J, Goddard ME, *et al.* Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood. *Bioinformatics* 2012;28:2540–2.
- 14 Yang J, Lee SH, Goddard ME, *et al.* GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 2011;88:76–82.
- 15 Hinks A, Cobb J, Marion MC, *et al.* Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. *Nat Genet* 2013;45:664–9.
- 16 Bondinas GP, Moustakas AK, Papadopoulos GK. The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function. *Immunogenetics* 2007;59:539–53.
- 17 Ombrello MJ, Remmers EF, Tachmazidou I, *et al.* HLA-DRB1\*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. *Proc Natl Acad Sci USA* 2015;112:15970–5.
- 18 Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. *Best Pract Res Clin Rheumatol* 2009;23:655–64.
- 19 Hinks A, Barton A, John S, *et al.* Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. *Arthritis Rheum* 2005;52:1694–9.
- 20 Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis—insights into pathogenesis. *Nat Rev Rheumatol* 2015;12:81–91.
- 21 Bowes J, Budu-Aggrey A, Huffmeier U, *et al.* Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. *Nat Commun* 2015;6:6046.
- 22 Okada Y, Han B, Tsoi LC, *et al.* Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. *Am J Hum Genet* 2014;95:162–72.
- 23 Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. *Curr Opin Rheumatol* 2011;23:437–43.
- 24 Daha NA, Toes RE. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? *Nat Rev Rheumatol* 2011;7:202–3.
- 25 van der Helm-van Mil AH, Huizinga TW. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. *Arthritis Res Ther* 2008;10:205.